Chronic PainNCT01888419
Investigation of the Pain Relieving Properties of Lipotransplantation After Treatment for Breast Cancer
A study testing Lipotransplantation in people with Chronic Pain, run by Aarhus University Hospital at 1 site in Denmark.
Trial summary
Background In Denmark, breast cancer is the most common fatal cancer in women with more than 4700 new cases annually. Unfortunately, up to 60% of women who are treated surgically for breast cancer, will experience chronic pain as a consequence of the treatment. Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Chronic Pain
- What is being tested?
- Lipotransplantation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteDenmark
- Study dates
- Oct 2014to Jan 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Previous diagnosed with and finished treatment for breast cancer
- Unilateral mastectomized
- Finished post operative radiotherapy minimum 6 months ago, if applicable.
- Pain in the area around the missing breast for minimum three months after radiotherapy was finished
- Pain equal to or above 3 on the Numeric Rating Scale for pain
- Verbal and written informed consent
Who cannot join
- Active breast cancer recurrence
- Other cancer disease
- Pain in the region around the removed breast before the mastectomy
- Active smokers
- Psychiatric illness that prevents informed consent
- Not able to understand and speak Danish
- Patients diagnosed with generalized pain conditions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective, Randomized Study of the Possible Pain Relieving and Scar Tissue Modifying Properties of Lipotransplantation in a "Post Breast Therapy Pain Syndrome" Setting
Background
In Denmark, breast cancer is the most common fatal cancer in women with more than 4700 new cases annually. Unfortunately, up to 60% of women who are treated surgically for breast cancer, will experience chronic pain as a consequence of the treatment. This state of chronic neuropathic pain is termed "Post Breast Therapy Pain Syndrome" or PBTPS.
Read more
The purpose of the study
The purpose of this study is to investigate whether transplantation of fat cells (lipotransplantation) to the pain affected mastectomy area, could have an analgesic effect in women who have developed PBTPS. Secondary, we wish to investigate if lipotransplantation has a beneficial effect on the quality of the skin and the scar in the area where the transplanted fat cells are placed.
Hypotheses
- Lipotransplantation to the area under the scar tissue and the area under the pain-afflicted area reduces the pain in women with PBTPS.
- The neuropathic pain in PBTPS is correlated to the number of free nerve endings crossing the border between the dermis and the epidermis
- Lipotransplantation have a beneficial effect on the scar tissue structure and improves the skin quality.
Patients
Women who have undergone treatment for breast cancer and subsequently developed PBTPS. A total of 32 patients with PBTPS will be included.
Methods
Patients will be randomly assigned to receive either lipotransplantation or no active treatment. At three follow-up visits, the perceived pain of the patient and the skin and scar quality will be scored. In addition, a 3-mm biopsy will be taken from the skin on both the missing and the healthy breast, and from the mastectomy scar.
The scoring of the perceived pain and the quality of the skin and the scar, allows us to investigate if the lipotransplantation have an effect on pain, and skin/scar quality. Additionally, the skin and scar biopsies will be examined on a microscopic level, in order to investigate why lipotransplantation has these effects.
Conclusion
In summary, the results of this project could help to increase our understanding of why some patients develop chronic neuropathic pain after mastectomy and radiotherapy. It is our hope that our results may contribute to the development of better and more effective treatment that will be beneficial for the project participants and future patients.
Read the detailed description
Background
In Denmark, breast cancer is the most common fatal cancer in women with more than 4700 new cases annually. All patients are treated according to national guidelines developed by the Danish Breast Cancer Cooperative Group (DBCG). Treatment primarily consists of surgical removal of all or parts of the breast and simultaneous removal of one-or lymph nodes in the ipsilateral axilla. Subsequently, there may be a need for additional treatment with chemotherapy, radiation and / or anti-hormonal therapy, in order to reduce the risk of recurrence.
Up to 60% of women who are treated surgically for breast cancer, will experience chronic pain as a consequence of the treatment. This condition was previously referred to as "Post Mastectomy Pain Syndrome", but because the condition is also seen after less extensive forms of breast cancer surgery, the condition is now termed "Post Therapy Breast Pain Syndrome" (PBTPS). PBTPS is defined as a neuropathic pain condition with pain localized to the axilla, the medial part of the upper arm, chest and or chest wall of the side of surgery, lasting more than three months after surgery and / or the end of treatment.
In 2011 Caviggioli et al. published a study where lipotransplantation to the mastectomy area was found to have a significant analgesic effect. The aforementioned study is to date the only published study in the field. However, it is not a randomized study. In order to obtain further evidence of the apparent beneficial effect of lipotransplantation on pain, the present study has been initiated.
Lipotransplantation is a fast and relatively non-invasive technique which is described in detail by Coleman et al.. Additionally, in a study from 2008, Klinger et al. found that lipotransplantation to burn scars in the face resulted in a significant improvement in the patient's skin and scar quality and also reduced pain in the treated areas. The theoretical basis for the scar and skin modifying effects of lipotransplantation has not yet been finally understood. To the best of our knowledge, no studies have systematically investigated and analysed the effects of lipotransplantation on the irradiated mastectomy area on a histological level.
The purpose of the study
The purpose of this study is to investigate whether lipotransplantation to the pain affected mastectomy area, could have an analgesic effect in women affected by Post Breast Therapy Pain Syndrome. Secondary, we wish to investigate the scar and skin modulating effects of lipotransplantation to the same area.
By carrying out immunohistochemical staining and subsequent stereoscopic microscopy of free nerve endings in the skin biopsies taken before and after lipotransplantationen we wish to determine whether changes in the number and type of free nerve endings is part of the mechanism of pain reduction.
Hypotheses
- Lipotransplantation to the area under the scar tissue and the area under the pain-afflicted area reduces the pain in women with PBTPS.
- The neuropathic pain in PBTPS is correlated to the number of free nerve endings crossing the border between the dermis and the epidermis
- Lipotransplantation have a beneficial effect on the scar tissue structure and improves the skin quality.
Patients
Women who have undergone unilateral mastectomy for breast cancer at Aarhus University Hospital, Aarhus, Denmark and, if applicable, has finished their adjuvant postoperative radiation therapy at least 6 months ago. Patients must have had pain localized to the area of the missing breast for at least three months after adjuvant radiation therapy ended. A total of 32 patients with PBTPS will be included.
Methods
Patients with PBTPS are randomly assigned to receive either lipotransplantation or no active treatment.
Regardless of randomization, the patient will be invited to three follow-up visits, respectively 3 and 6 months after inclusion/surgery. At each of the outpatient visits the participant will be asked to complete the DoloTest ® , VAS pain score and the Patient Scar Assessment Scale. The clinician will complete the Observer Scar Assessment Scale and record the consumption of pain medication. DoloTest ® is a validated, visual analogue questionnaire designed to assess the patients experienced pain and impact on the patients daily life. Three 3-mm punch biopsies will be taken at inclusion, one from the mastectomy scar, one from the skin 2 cm above the mastectomy scar in the medioclavicular line, and one from the healthy skin on the health breast in an area corresponding to the other skin biopsy.
The skin punch biopsies from the pain afflicted area will be fixed in 4% phosphate buffered paraformaldehyde. After freezing, the tissue samples are cut into 50-micron thick sections. Systematically sampled sections immunostained with rabbit anti-human Protein Gene Product 9.5 (a neuron-specific protein), and DAB-marked goat anti-rabbit as the secondary antibody. The sections are then microscoped in an Olympus BX51 light microscope with an Olympus DP71 digital camera and Prior motorized board connected to a computer with Newcast stereology software. Two goals can then be calculated: 1) the number of free nerve endings, which crosses the border between dermis and epidermis per mm 2) the average nerve fibre length density in the epidermis and / or dermis.
The skin punch biopsies from the mastectomy scar are fixed in formaldehyde for embedding in paraffin. The tissue samples are cut into 1-2 micron thick sections and stained with Picrosirius red (PR) colour. By using polarized light microscopy, the various subtypes of collagen fibres may be visualized and differentiated. The thicker collagen fibres (type I) are red-orange-yellow and the thinner collagen fibres (type III) are green. Furthermore, the sections will be stained for elastin. Quantitatively, by means of the above-mentioned method, changes in the volume fraction of collagen type I and III, and elastin may be measured.
Statistical analyzes
The minimal clinically relevant difference the study is looking for, is a Visual Analog Pain score difference of 3. The common standard deviation was estimated from a similar study by Caviggioli et al. in 2011, and set to be 2.96 on the Visual Analog Pain scale. We assume that our standard deviation (SD) will be the same. Using the following formula: N = (Za + Zb)2 x SD2 / dif2 where Za and Zb are the standardized normal deviations corresponding to the selected levels of significance, SD is Standard Deviation and dif is the minimal clinically relevant difference the study is looking for. The result is 16 patients in each arm, totalling 32 patients, when the significance level is set at 5% and the power of the study is set to 80%. Statistical analyzes will be performed in collaboration with a biostatistician from the Health Sciences Institution, Aarhus University, Denmark.
Economic Conditions
The project is supported by: Faculty of Health Sciences, University of Aarhus with three full time equivalents, which is used to pay for full-time academic staff. Other project expenses are to be covered by independent foundations and endowments that do not have an influence on the study. None of the personnel in the project have a financial interest in the project.
Compensation to the participating patients
The participating patients in the study will not receive any financial compensation. However, documented travel expenses will be reimbursed.
Recruitment of participants
Patients are primarily recruited from a previous study, were a questionnaire was sent to all women having received an unilateral mastectomy at Aarhus University Hospital, in the period from 2009 to 2013. In the questionnaire, patients were asked to evaluate their pain in the different areas pertaining to PBTPS, and if they would allow our department to contact them in regards to the present study. If patients fulfilled the inclusion criteria, they are contacted by the primary investigator by telephone, and a meeting were the details of the study are presented is arranged. Patients with PBTPS could also be recruited during their routine visits at the department of oncology.
The patients will always be offered at least 24 hours of consideration before deciding to give written consent to participate in the study. With the signing of the consent form, the patient accepts the terms and conditions in the study. The patient may at any time and without justification withdraw her consent to participate, without her decision affecting her present or future treatment or any other rights the patient may have.
Publication of results
Negative, inconclusive and positive results from the study will be published in internationally recognized, peer-reviewed, English-language journals with an interest in the field.
Ethical statement, side effects and risks
In the present project, data will be treated confidentially in accordance with the Danish Act on Processing of Personal Data. Participants shall be informed both in writing and orally prior to deciding to participate in the study. The participants are thus fully aware of the projects purpose, background and methods, as well as what is expected from the patient's role as a participant.
The participating patients are in the lipotransplantation group, offered an active treatment, which if the current study program can confirm the foreign study, hopefully reduces their daily pain and discomfort and thereby also their consumption of analgesia. If the project provides positive results, the control group will, after the study has ended, be offered the same active treatment.
The patients, which only after informed consent, is part of the project will, in connection with:
- Lipotransplantation in general anaesthesia; only be exposed to the risk associated with general anaesthesia. The patients in the present study have in relation to their previous surgery for breast cancer been exposed to one or more interventions in general anaesthesia.
- Risks related to the actual lipotransplantation. At the donor site, there is a risk for short-term tenderness and temporary discolouration. In the long term, a slightly rough surface of the skin may arise. The advantage of the harvest of the fat graft is that the patient achieves a visible improvement of the contour at the donor site.
- The risk related to the skin punch biopsies: apart from a small scar 1-3 mm corresponding to the place where the biopsy is collected, there is not assessed to any risk of permanent injury or damage.
All interventions are carried out by experienced specialists in plastic surgery with several years experience with lipotransplantation. The general anaesthesia is performed by specialists in anaesthesiology, which are all part of the permanent team at the plastic surgery department and therefore familiar with providing anaesthesia during the described procedures.
- Conditions
- Chronic Pain
- Being tested
- Lipotransplantation
- Keywords
- Post Breast Therapy Pain Syndrome, Lipotransplantation, Breast Cancer, Pain
- Medical subject headings
- Chronic Pain, Breast Neoplasms, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LipotransplantationOther
Also called Fat grafting, Fat transplantation
Lipotransplantation in general anaesthesia to the mastectomy site
| Study group | Role | What they receive |
|---|---|---|
| No active treatment | No intervention | Clinical follow-up, no active intervention. |
| Lipotransplantation | Experimental | Lipotransplantation in general anaesthesia to the mastectomy site. Receives: Other: Lipotransplantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain in the mastectomy area
The pain in the area around the mastectomy will be measured using visual analog scales (DoloTest), at inclusion of the patient, and at three follow-up visits 3, 6 and 12 months after inclusion.
Measured: one year
Secondary outcomes (5)
Collagen in the mastectomy scar
Changes in the proportions of collagen type I and III in the mastectomy scar.
Measured: One year
Elastin content in the mastectomy scar
Changes in the elastin content of the mastectomy scar.
Measured: One year
Free nerve endings crossing between the dermis and the epidermis
Changes in the number of free nerve endings crossing the border between the dermis and the epidermis per millimeter in the skin of the pain afflicted area around the mastectomy scar.
Measured: One year
Mastectomy scar quality
Changes in the mastectomy scar quality, measured using the Patient and Observer Scar Assessment Scale.
Measured: One year
Analgesic consumption
Changes in the analgesic consumption of the patients included in the study.
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2013 (estimated)
- Study startOct 2014
- Primary completionJan 2016
- Study completionJan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Chronic PainStudies of the same condition, open and under way.
- More trials run by Aarhus University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aarhus University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Aarhus
- Responsible party
- Principal investigator, Alexander Juhl Andersen, Aarhus University Hospital
- Investigators
- Alexander Juhl Andersen, M.D., Principal investigator, University of Aarhus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01888419
- Sponsor's protocol ID
- PBTPS 1-10-72-76-13
- Status last verified
- Feb 2016
- First submitted
- 25 Jun 2013
- Last updated
- 15 Feb 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985-92. doi: 10.1001/jama.2009.1568.
PubMed 19903919Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. 2011 Jul;12(7):725-46. doi: 10.1016/j.jpain.2010.12.005. Epub 2011 Mar 24.
PubMed 21435953Carpenter JS, Andrykowski MA, Sloan P, Cunningham L, Cordova MJ, Studts JL, McGrath PC, Sloan D, Kenady DE. Postmastectomy/postlumpectomy pain in breast cancer survivors. J Clin Epidemiol. 1998 Dec;51(12):1285-92. doi: 10.1016/s0895-4356(98)00121-8.
PubMed 10086821Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain. 1996 Aug;66(2-3):195-205. doi: 10.1016/0304-3959(96)03064-3.
PubMed 8880841Lundstedt D, Gustafsson M, Steineck G, Malmstrom P, Alsadius D, Sundberg A, Wilderang U, Holmberg E, Johansson KA, Karlsson P. Risk factors of developing long-lasting breast pain after breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):71-8. doi: 10.1016/j.ijrobp.2011.05.065. Epub 2011 Nov 11.
PubMed 22079722Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005 Jan 31;92(2):225-30. doi: 10.1038/sj.bjc.6602304.
PubMed 15655557Peuckmann V, Ekholm O, Rasmussen NK, Groenvold M, Christiansen P, Moller S, Eriksen J, Sjogren P. Chronic pain and other sequelae in long-term breast cancer survivors: nationwide survey in Denmark. Eur J Pain. 2009 May;13(5):478-85. doi: 10.1016/j.ejpain.2008.05.015. Epub 2008 Jul 16.
PubMed 18635381Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008 Aug 19;99(4):604-10. doi: 10.1038/sj.bjc.6604534.
PubMed 18682712Ducic I, Seiboth LA, Iorio ML. Chronic postoperative breast pain: danger zones for nerve injuries. Plast Reconstr Surg. 2011 Jan;127(1):41-46. doi: 10.1097/PRS.0b013e3181f9587f.
PubMed 21200198Watson PNC, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain. 1992 Dec;51(3):375-379. doi: 10.1016/0304-3959(92)90223-X.
PubMed 1491864Eija K, Tiina T, J NP. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996 Feb;64(2):293-302. doi: 10.1016/0304-3959(95)00138-7.
PubMed 8740607Caviggioli F, Maione L, Forcellini D, Klinger F, Klinger M. Autologous fat graft in postmastectomy pain syndrome. Plast Reconstr Surg. 2011 Aug;128(2):349-352. doi: 10.1097/PRS.0b013e31821e70e7.
PubMed 21788826Coleman SR, Saboeiro AP. Fat grafting to the breast revisited: safety and efficacy. Plast Reconstr Surg. 2007 Mar;119(3):775-85; discussion 786-7. doi: 10.1097/01.prs.0000252001.59162.c9.
PubMed 17312477Klinger M, Marazzi M, Vigo D, Torre M. Fat injection for cases of severe burn outcomes: a new perspective of scar remodeling and reduction. Aesthetic Plast Surg. 2008 May;32(3):465-9. doi: 10.1007/s00266-008-9122-1.
PubMed 18305985Trojahn Kolle SF, Oliveri RS, Glovinski PV, Elberg JJ, Fischer-Nielsen A, Drzewiecki KT. Importance of mesenchymal stem cells in autologous fat grafting: a systematic review of existing studies. J Plast Surg Hand Surg. 2012 Apr;46(2):59-68. doi: 10.3109/2000656X.2012.668326.
PubMed 22471250
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Randomized Study of the Possible Pain Relieving and Scar Tissue Modifying Properties of Lipotransplantation in a "Post Breast Therapy Pain Syndrome" Setting
- ClinicalTrials.gov ID
- NCT01888419
- Acronym / sponsor ID
- PBTPS 1-10-72-76-13
- Conditions
- Chronic Pain
- Keywords
- Post Breast Therapy Pain Syndrome, Lipotransplantation, Breast Cancer, Pain
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Aarhus University HospitalUniversity, hospital or other
- Collaborators
- University of Aarhus
- Study start
- Oct 2014
- Primary completion
- Jan 2016 (actual)
- Study completion
- Jan 2016 (actual)
- First posted
- 27 Jun 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background
In Denmark, breast cancer is the most common fatal cancer in women with more than 4700 new cases annually. Unfortunately, up to 60% of women who are treated surgically for breast cancer, will experience chronic pain as a consequence of the treatment. This state of chronic neuropathic pain is termed "Post Breast Therapy Pain Syndrome" or PBTPS.
The purpose of the study
The purpose of this study is to investigate whether transplantation of fat cells (lipotransplantation) to the pain affected mastectomy area, could have an analgesic effect in women who have developed PBTPS. Secondary, we wish to investigate if lipotransplantation has a beneficial effect on the quality of the skin and the scar in the area where the transplanted fat cells are placed.
Hypotheses
- Lipotransplantation to the area under the scar tissue and the area under the pain-afflicted area reduces the pain in women with PBTPS.
- The neuropathic pain in PBTPS is correlated to the number of free nerve endings crossing the border between the dermis and the epidermis
- Lipotransplantation have a beneficial effect on the scar tissue structure and improves the skin quality.
Patients
Women who have undergone treatment for breast cancer and subsequently developed PBTPS. A total of 32 patients with PBTPS will be included.
Methods
Patients will be randomly assigned to receive either lipotransplantation or no active treatment. At three follow-up visits, the perceived pain of the patient and the skin and scar quality will be scored. In addition, a 3-mm biopsy will be taken from the skin on both the missing and the healthy breast, and from the mastectomy scar.
The scoring of the perceived pain and the quality of the skin and the scar, allows us to investigate if the lipotransplantation have an effect on pain, and skin/scar quality. Additionally, the skin and scar biopsies will be examined on a microscopic level, in order to investigate why lipotransplantation has these effects.
Conclusion
In summary, the results of this project could help to increase our understanding of why some patients develop chronic neuropathic pain after mastectomy and radiotherapy. It is our hope that our results may contribute to the development of better and more effective treatment that will be beneficial for the project participants and future patients.
Detailed description
Background
In Denmark, breast cancer is the most common fatal cancer in women with more than 4700 new cases annually. All patients are treated according to national guidelines developed by the Danish Breast Cancer Cooperative Group (DBCG). Treatment primarily consists of surgical removal of all or parts of the breast and simultaneous removal of one-or lymph nodes in the ipsilateral axilla. Subsequently, there may be a need for additional treatment with chemotherapy, radiation and / or anti-hormonal therapy, in order to reduce the risk of recurrence.
Up to 60% of women who are treated surgically for breast cancer, will experience chronic pain as a consequence of the treatment. This condition was previously referred to as "Post Mastectomy Pain Syndrome", but because the condition is also seen after less extensive forms of breast cancer surgery, the condition is now termed "Post Therapy Breast Pain Syndrome" (PBTPS). PBTPS is defined as a neuropathic pain condition with pain localized to the axilla, the medial part of the upper arm, chest and or chest wall of the side of surgery, lasting more than three months after surgery and / or the end of treatment.
In 2011 Caviggioli et al. published a study where lipotransplantation to the mastectomy area was found to have a significant analgesic effect. The aforementioned study is to date the only published study in the field. However, it is not a randomized study. In order to obtain further evidence of the apparent beneficial effect of lipotransplantation on pain, the present study has been initiated.
Lipotransplantation is a fast and relatively non-invasive technique which is described in detail by Coleman et al.. Additionally, in a study from 2008, Klinger et al. found that lipotransplantation to burn scars in the face resulted in a significant improvement in the patient's skin and scar quality and also reduced pain in the treated areas. The theoretical basis for the scar and skin modifying effects of lipotransplantation has not yet been finally understood. To the best of our knowledge, no studies have systematically investigated and analysed the effects of lipotransplantation on the irradiated mastectomy area on a histological level.
The purpose of the study
The purpose of this study is to investigate whether lipotransplantation to the pain affected mastectomy area, could have an analgesic effect in women affected by Post Breast Therapy Pain Syndrome. Secondary, we wish to investigate the scar and skin modulating effects of lipotransplantation to the same area.
By carrying out immunohistochemical staining and subsequent stereoscopic microscopy of free nerve endings in the skin biopsies taken before and after lipotransplantationen we wish to determine whether changes in the number and type of free nerve endings is part of the mechanism of pain reduction.
Hypotheses
- Lipotransplantation to the area under the scar tissue and the area under the pain-afflicted area reduces the pain in women with PBTPS.
- The neuropathic pain in PBTPS is correlated to the number of free nerve endings crossing the border between the dermis and the epidermis
- Lipotransplantation have a beneficial effect on the scar tissue structure and improves the skin quality.
Patients
Women who have undergone unilateral mastectomy for breast cancer at Aarhus University Hospital, Aarhus, Denmark and, if applicable, has finished their adjuvant postoperative radiation therapy at least 6 months ago. Patients must have had pain localized to the area of the missing breast for at least three months after adjuvant radiation therapy ended. A total of 32 patients with PBTPS will be included.
Methods
Patients with PBTPS are randomly assigned to receive either lipotransplantation or no active treatment.
Regardless of randomization, the patient will be invited to three follow-up visits, respectively 3 and 6 months after inclusion/surgery. At each of the outpatient visits the participant will be asked to complete the DoloTest ® , VAS pain score and the Patient Scar Assessment Scale. The clinician will complete the Observer Scar Assessment Scale and record the consumption of pain medication. DoloTest ® is a validated, visual analogue questionnaire designed to assess the patients experienced pain and impact on the patients daily life. Three 3-mm punch biopsies will be taken at inclusion, one from the mastectomy scar, one from the skin 2 cm above the mastectomy scar in the medioclavicular line, and one from the healthy skin on the health breast in an area corresponding to the other skin biopsy.
The skin punch biopsies from the pain afflicted area will be fixed in 4% phosphate buffered paraformaldehyde. After freezing, the tissue samples are cut into 50-micron thick sections. Systematically sampled sections immunostained with rabbit anti-human Protein Gene Product 9.5 (a neuron-specific protein), and DAB-marked goat anti-rabbit as the secondary antibody. The sections are then microscoped in an Olympus BX51 light microscope with an Olympus DP71 digital camera and Prior motorized board connected to a computer with Newcast stereology software. Two goals can then be calculated: 1) the number of free nerve endings, which crosses the border between dermis and epidermis per mm 2) the average nerve fibre length density in the epidermis and / or dermis.
The skin punch biopsies from the mastectomy scar are fixed in formaldehyde for embedding in paraffin. The tissue samples are cut into 1-2 micron thick sections and stained with Picrosirius red (PR) colour. By using polarized light microscopy, the various subtypes of collagen fibres may be visualized and differentiated. The thicker collagen fibres (type I) are red-orange-yellow and the thinner collagen fibres (type III) are green. Furthermore, the sections will be stained for elastin. Quantitatively, by means of the above-mentioned method, changes in the volume fraction of collagen type I and III, and elastin may be measured.
Statistical analyzes
The minimal clinically relevant difference the study is looking for, is a Visual Analog Pain score difference of 3. The common standard deviation was estimated from a similar study by Caviggioli et al. in 2011, and set to be 2.96 on the Visual Analog Pain scale. We assume that our standard deviation (SD) will be the same. Using the following formula: N = (Za + Zb)2 x SD2 / dif2 where Za and Zb are the standardized normal deviations corresponding to the selected levels of significance, SD is Standard Deviation and dif is the minimal clinically relevant difference the study is looking for. The result is 16 patients in each arm, totalling 32 patients, when the significance level is set at 5% and the power of the study is set to 80%. Statistical analyzes will be performed in collaboration with a biostatistician from the Health Sciences Institution, Aarhus University, Denmark.
Economic Conditions
The project is supported by: Faculty of Health Sciences, University of Aarhus with three full time equivalents, which is used to pay for full-time academic staff. Other project expenses are to be covered by independent foundations and endowments that do not have an influence on the study. None of the personnel in the project have a financial interest in the project.
Compensation to the participating patients
The participating patients in the study will not receive any financial compensation. However, documented travel expenses will be reimbursed.
Recruitment of participants
Patients are primarily recruited from a previous study, were a questionnaire was sent to all women having received an unilateral mastectomy at Aarhus University Hospital, in the period from 2009 to 2013. In the questionnaire, patients were asked to evaluate their pain in the different areas pertaining to PBTPS, and if they would allow our department to contact them in regards to the present study. If patients fulfilled the inclusion criteria, they are contacted by the primary investigator by telephone, and a meeting were the details of the study are presented is arranged. Patients with PBTPS could also be recruited during their routine visits at the department of oncology.
The patients will always be offered at least 24 hours of consideration before deciding to give written consent to participate in the study. With the signing of the consent form, the patient accepts the terms and conditions in the study. The patient may at any time and without justification withdraw her consent to participate, without her decision affecting her present or future treatment or any other rights the patient may have.
Publication of results
Negative, inconclusive and positive results from the study will be published in internationally recognized, peer-reviewed, English-language journals with an interest in the field.
Ethical statement, side effects and risks
In the present project, data will be treated confidentially in accordance with the Danish Act on Processing of Personal Data. Participants shall be informed both in writing and orally prior to deciding to participate in the study. The participants are thus fully aware of the projects purpose, background and methods, as well as what is expected from the patient's role as a participant.
The participating patients are in the lipotransplantation group, offered an active treatment, which if the current study program can confirm the foreign study, hopefully reduces their daily pain and discomfort and thereby also their consumption of analgesia. If the project provides positive results, the control group will, after the study has ended, be offered the same active treatment.
The patients, which only after informed consent, is part of the project will, in connection with:
- Lipotransplantation in general anaesthesia; only be exposed to the risk associated with general anaesthesia. The patients in the present study have in relation to their previous surgery for breast cancer been exposed to one or more interventions in general anaesthesia.
- Risks related to the actual lipotransplantation. At the donor site, there is a risk for short-term tenderness and temporary discolouration. In the long term, a slightly rough surface of the skin may arise. The advantage of the harvest of the fat graft is that the patient achieves a visible improvement of the contour at the donor site.
- The risk related to the skin punch biopsies: apart from a small scar 1-3 mm corresponding to the place where the biopsy is collected, there is not assessed to any risk of permanent injury or damage.
All interventions are carried out by experienced specialists in plastic surgery with several years experience with lipotransplantation. The general anaesthesia is performed by specialists in anaesthesiology, which are all part of the permanent team at the plastic surgery department and therefore familiar with providing anaesthesia during the described procedures.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| No active treatment | No intervention | –Clinical follow-up, no active intervention. |
| Lipotransplantation | Experimental | Other: LipotransplantationLipotransplantation in general anaesthesia to the mastectomy site. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Previous diagnosed with and finished treatment for breast cancer
- Unilateral mastectomized
- Finished post operative radiotherapy minimum 6 months ago, if applicable.
- Pain in the area around the missing breast for minimum three months after radiotherapy was finished
- Pain equal to or above 3 on the Numeric Rating Scale for pain
Key exclusion criteria (7 listed)
- Active breast cancer recurrence
- Other cancer disease
- Pain in the region around the removed breast before the mastectomy
- Active smokers
- Psychiatric illness that prevents informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LipotransplantationAlso: Fat grafting, Fat transplantationLipotransplantation in general anaesthesia to the mastectomy site | Other | Lipotransplantation |
Primary outcome
Pain in the mastectomy area
Time frame: one year
The pain in the area around the mastectomy will be measured using visual analog scales (DoloTest), at inclusion of the patient, and at three follow-up visits 3, 6 and 12 months after inclusion.
5 secondary outcomes
Collagen in the mastectomy scar
Time frame: One year
Elastin content in the mastectomy scar
Time frame: One year
Free nerve endings crossing between the dermis and the epidermis
Time frame: One year
Mastectomy scar quality
Time frame: One year
Analgesic consumption
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2016.
- Background: PubMed 19903919Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985-92. doi: 10.1001/jama.2009.1568.
- Background: PubMed 21435953Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. 2011 Jul;12(7):725-46. doi: 10.1016/j.jpain.2010.12.005. Epub 2011 Mar 24.
- Background: PubMed 10086821Carpenter JS, Andrykowski MA, Sloan P, Cunningham L, Cordova MJ, Studts JL, McGrath PC, Sloan D, Kenady DE. Postmastectomy/postlumpectomy pain in breast cancer survivors. J Clin Epidemiol. 1998 Dec;51(12):1285-92. doi: 10.1016/s0895-4356(98)00121-8.
- Background: PubMed 8880841Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain. 1996 Aug;66(2-3):195-205. doi: 10.1016/0304-3959(96)03064-3.
- Background: PubMed 22079722Lundstedt D, Gustafsson M, Steineck G, Malmstrom P, Alsadius D, Sundberg A, Wilderang U, Holmberg E, Johansson KA, Karlsson P. Risk factors of developing long-lasting breast pain after breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):71-8. doi: 10.1016/j.ijrobp.2011.05.065. Epub 2011 Nov 11.
- Background: PubMed 15655557Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005 Jan 31;92(2):225-30. doi: 10.1038/sj.bjc.6602304.
- Background: PubMed 18635381Peuckmann V, Ekholm O, Rasmussen NK, Groenvold M, Christiansen P, Moller S, Eriksen J, Sjogren P. Chronic pain and other sequelae in long-term breast cancer survivors: nationwide survey in Denmark. Eur J Pain. 2009 May;13(5):478-85. doi: 10.1016/j.ejpain.2008.05.015. Epub 2008 Jul 16.
- Background: PubMed 18682712Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008 Aug 19;99(4):604-10. doi: 10.1038/sj.bjc.6604534.
- Background: PubMed 21200198Ducic I, Seiboth LA, Iorio ML. Chronic postoperative breast pain: danger zones for nerve injuries. Plast Reconstr Surg. 2011 Jan;127(1):41-46. doi: 10.1097/PRS.0b013e3181f9587f.
- Background: PubMed 1491864Watson PNC, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain. 1992 Dec;51(3):375-379. doi: 10.1016/0304-3959(92)90223-X.
- Background: PubMed 8740607Eija K, Tiina T, J NP. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996 Feb;64(2):293-302. doi: 10.1016/0304-3959(95)00138-7.
- Background: PubMed 21788826Caviggioli F, Maione L, Forcellini D, Klinger F, Klinger M. Autologous fat graft in postmastectomy pain syndrome. Plast Reconstr Surg. 2011 Aug;128(2):349-352. doi: 10.1097/PRS.0b013e31821e70e7.
- The Danish Cancer Society: Incidence of breast cancer in DenmarkLink provided by the sponsor.
- The Danish Breast Cancer Group: Responsible for developing national guidelines for the treatment of breast cancer in DenmarkLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Chronic Pain
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effect of Lumbar Stabilization Exercises With and Without YTWL (Scapular Stabilization Exercises) on Reducing Chronic Low Back Pain and Related Disability. A Randomized Clinical Trial,
Chronic Non Specific Mechanical Low Back Pain
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexander Juhl Andersen, M.D. principal investigator
University of Aarhus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lipotransplantation in people with Chronic Pain, run by Aarhus University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain in the mastectomy area (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01888419, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2016.